640 followers
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myelo... https://t.co/yW0eQ4ogQt https://t.co/JWyErNB66X
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myelo... https://t.co/yW0eQ4ogQt https://t.co/JWyErNB66X